MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.4951
-0.0258
-4.95%
Opening 13:58 04/24 EDT
OPEN
0.5137
PREV CLOSE
0.5209
HIGH
0.5230
LOW
0.4900
VOLUME
792.25K
TURNOVER
0
52 WEEK HIGH
1.780
52 WEEK LOW
0.2911
MARKET CAP
102.73M
P/E (TTM)
-0.3350
1D
5D
1M
3M
1Y
5Y
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024. Presentations will focus on the progression of Sangamo’s neurology-focused pre-clinical pipeline. Sangamo is a genomic medicine company developing treatments for neurological diseases.
Barchart · 2d ago
Weekly Report: what happened at SGMO last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at SGMO last week (0408-0412)?
Weekly Report · 04/15 09:23
Weekly Report: what happened at SGMO last week (0401-0405)?
Weekly Report · 04/08 09:24
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at SGMO last week (0325-0329)?
Weekly Report · 04/01 09:24
Weekly Report: what happened at SGMO last week (0318-0322)?
Weekly Report · 03/25 09:25
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Sangamo Therapeutics, Inc. Shares have retraced a considerable 36% in the last month. The company's price-to-sales ratio of 0.8x is lower than the industry average. Sangamo has been growing revenue less than most other companies in the biotech industry. The low P/S ratio is typical of a company expected to perform poorly in the future.
Simply Wall St · 03/23 14:12
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.